VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company’s proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-19. The study will assess the ability of VB-201 to prevent clinical deterioration and reduce morbidity and mortality in patients with severe COVID-19.
"While vaccines offer a major development in this pandemic, there is still a crucial unmet global need for new treatments for severe COVID patients," said Prof. Dror Harats, Chief Executive Officer of VBL Therapeutics. "Manufacturing and cold-chain logistics limit access to vaccines in many regions in the world and at the same time, new and aggressive viral mutations are being identified. There is an understanding that the therapeutic arsenal against COVID must be enriched, both to combat the current pandemic as well as for future viral outbreaks. We believe that, as a safe and affordable oral therapy, VB-201 has the potential to bridge this gap by limiting the life-threatening hyper-inflammation in this deadly disease.”
VB-201 is designed to offer differentiation from other immune modulators evaluated as treatments for COVID, and its anti-inflammatory activity in the cardiovascular system may benefit patients with COVID-related Kawasaki-like multisystem inflammatory syndrome. Studied in over 600 subjects, VB-201 previously demonstrated proof of concept in a Phase 2 study in vascular inflammation, meeting the primary endpoint of the trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.